Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-418 in Limb Girdle Muscular Dystrophy Type 2I
NCT04800874Phase 2Active, not recruiting
- Sponsor
- ML Bio Solutions
- Start
- Feb 2021
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribitol in limb-girdle muscular dystrophy type 2I (LGMD2I), sponsored by ML Bio Solutions. Started Feb 2021; status: active, not recruiting.
02
Drugs
ribitol
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on NCT04800874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800874.